📊 ORGS Key Takeaways
Is Orgenesis Inc. (ORGS) a Good Investment?
Orgenesis is in acute financial distress with negative stockholders' equity (-$37.5M), critically depleted cash reserves ($78K), and a current ratio of 0.03x indicating imminent insolvency. While revenue grew 95% YoY, negative gross margins (-86.3%) reveal fundamental business model failure—the company loses money on every sale and burns $17.1M annually in operating cash, with insufficient resources to reach profitability.
Fundamentals indicate acute financial distress: negative gross margin, massive operating losses, and negative equity with minimal cash and a 0.03x current ratio. While revenue grew ~95% YoY, it is from a tiny base and accompanied by deteriorated unit economics. Survival appears dependent on near‑term external financing or restructuring, with high dilution or insolvency risk.
Why Buy Orgenesis Inc. Stock? ORGS Key Strengths
- Revenue growth of 95.3% YoY demonstrates active market traction
- Operating in regulated pharmaceutical sector with established infrastructure
- Some positive top-line activity despite pre-profitability stage
- Rapid YoY revenue growth off a small base
- Low capital expenditure requirements
- Potential operating leverage if unit economics turn positive
ORGS Stock Risks: Orgenesis Inc. Investment Risks
- Negative stockholders' equity of -$37.5M indicates technical insolvency
- Critical liquidity crisis: current ratio of 0.03x with only $78K cash reserves
- Negative gross margins (-86.3%) reveal fundamental unit economics failure
- Annual operating cash burn of $17.1M with severely limited runway
- Liabilities ($38.9M) exceed total assets ($1.4M) by 27x
- Zero insider stock purchases in last 90 days suggests loss of management confidence
- Negative equity means shareholders have no residual claim in bankruptcy scenario
- Extreme liquidity shortfall (current ratio 0.03x; cash ~$78k) and going-concern risk
- Negative equity and large liabilities (~$38.9M) limit financing flexibility
- Negative gross margin and heavy operating losses indicate non-viable unit economics
Key Metrics to Watch
- Monthly cash burn rate and estimated runway to depletion
- Gross margin inflection point—must become positive for viability
- Success of capital raise or debt restructuring initiatives
- Revenue per unit economics and path to gross profitability
- Quarterly operating cash flow (burn rate)
- Gross margin
Orgenesis Inc. (ORGS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ORGS Profit Margin, ROE & Profitability Analysis
ORGS vs Healthcare Sector: How Orgenesis Inc. Compares
How Orgenesis Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Orgenesis Inc. Stock Overvalued? ORGS Valuation Analysis 2026
Based on fundamental analysis, Orgenesis Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Orgenesis Inc. Balance Sheet: ORGS Debt, Cash & Liquidity
ORGS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Orgenesis Inc.'s revenue has declined by 83% over the 5-year period, indicating business contraction. The most recent EPS of $19.08 reflects profitable operations.
ORGS Revenue Growth, EPS Growth & YoY Performance
ORGS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $110.0K | -$3.7M | $0.12 |
| Q2 2024 | $113.0K | -$8.9M | $0.23 |
| Q1 2024 | $141.0K | -$9.8M | $0.29 |
| Q3 2023 | $110.0K | -$1.4M | $0.05 |
| Q2 2023 | $6.7M | -$4.1M | $0.15 |
| Q1 2023 | $6.6M | -$4.0M | N/A |
| Q3 2022 | $7.6M | -$1.4M | N/A |
| Q2 2022 | $6.7M | -$2.7M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Orgenesis Inc. Dividends, Buybacks & Capital Allocation
ORGS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Orgenesis Inc. (CIK: 0001460602)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ORGS
What is the AI rating for ORGS?
Orgenesis Inc. (ORGS) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ORGS's key strengths?
Claude: Revenue growth of 95.3% YoY demonstrates active market traction. Operating in regulated pharmaceutical sector with established infrastructure. ChatGPT: Rapid YoY revenue growth off a small base. Low capital expenditure requirements.
What are the risks of investing in ORGS?
Claude: Negative stockholders' equity of -$37.5M indicates technical insolvency. Critical liquidity crisis: current ratio of 0.03x with only $78K cash reserves. ChatGPT: Extreme liquidity shortfall (current ratio 0.03x; cash ~$78k) and going-concern risk. Negative equity and large liabilities (~$38.9M) limit financing flexibility.
What is ORGS's revenue and growth?
Orgenesis Inc. reported revenue of $1.0M.
Does ORGS pay dividends?
Orgenesis Inc. does not currently pay dividends.
Where can I find ORGS SEC filings?
Official SEC filings for Orgenesis Inc. (CIK: 0001460602) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ORGS's EPS?
Orgenesis Inc. has a diluted EPS of $11.44.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ORGS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Orgenesis Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ORGS stock overvalued or undervalued?
Valuation metrics for ORGS: ROE of N/A (sector avg: 15%), net margin of -4,653.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ORGS stock in 2026?
Our dual AI analysis gives Orgenesis Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ORGS's free cash flow?
Orgenesis Inc.'s operating cash flow is $-17.1M, with capital expenditures of $263.0K. FCF margin is -1,675.3%.
How does ORGS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4,653.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.03 (avg: 2).